Vaborbactam (VAB; formerly RPX7009) is a novel beta-lactamase inhibitor based on a cyclic boronic acid pharmacophore with potent inhibitory activity against Ambler class A and C beta-lactamases. It has been co-formulated with meropenem to restore its activity against Klebsiella pneumoniae carbapenemases (KPC). VAB does not inhibit class B or D carbapenemases, nor does it improve the activity of meropenem against multidrug-resistant nonfermenting gram-negative bacilli, notably Acinetobacter spp. and Pseudomonas aeruginosa. The purpose of this article is to review existing data pertaining to the biochemistry, mechanism of action, pharmacokinetics/pharmacodynamics, in vitro activity, and current progress in clinical trials of meropenem and VAB (MV). Phase 1 studies have demonstrated single and multiple doses of VAB up to 2000 mg, alone or in combination with meropenem 2000 mg administered as a prolonged infusion over 3 hours, are well tolerated with an adverse effect profile similar to that of meropenem monotherapy. The available data suggest preexisting resistance among KPC-producing isolates is rare. Strains with elevated MICs have been characterized by multiple resistance determinants including porin defects, increased drug efflux, and increased blaKPC expression. It remains uncertain whether multifactorial resistance will emerge during MV treatment and with more widespread use. Early data are positive for complicated urinary tract infections and MV compared with best available therapy in patients with serious carbapenem-resistant Enterobacteriaciae (CRE) infections. As clinicians contemplate how to incorporate MV into CRE treatment strategies, it will be important to track and understand resistance, discern the role, if any, of combination therapy in enhancing efficacy and/or preserving activity, and define the specific therapeutic niche of MV among the expanding anti-CRE armamentarium. KEY WORDS meropenem and vaborbactam, carbapenem-resistant Enterobacteriaceae, Klebsiella pneumoniae carbapenemase, multidrug resistant.
States is Klebsiella pneumoniae carbapenemase (KPC), an Ambler class A enzyme that utilizes serine at the active site to facilitate hydrolysis of nearly all currently available beta-lactam antibiotics. 2 BlaKPC, the gene that encodes KPC, is often accompanied by other genes that encode resistance to multiple classes of antibiotics, posing a serious treatment challenge. 3 Historically, treatment with a single active agent, such as tigecycline, colistin, or an aminoglycoside, resulted in unacceptably high mortality (25-45%) . [4] [5] [6] [7] The poor performance of monotherapy was most apparent in critically ill patients with severe sepsis or septic shock, with mortality rates ranging from 50% to 80%. 4, 6 Combination regimens using up to three agents was considered standard; however, the marginal benefits of this approach were often mitigated by overlapping toxicities. 6 In response to escalating concerns about poor outcomes associated with infections caused by MDR pathogens coupled with a weak antibiotic pipeline, a variety of incentives to spur the development of new antibiotics targeting MDR pathogens have been implemented. There are encouraging signs that the antibiotic pipeline is improving. The recent approval of a number of new agents represents meaningful progress for patients and public health; however, only one new antibiotic so far, ceftazidime-avibactam, has shown appreciable activity against our most urgent threat, carbapenem-resistant Enterobacteriaceae (CRE). The introduction of ceftazidimeavibactam has changed the landscape of CRE treatment with real-world data finally demonstrating improved efficacy and safety outcomes compared with regimens of older, more-toxic agents. 8, 9 However, it has also become clear that ceftazidime-avibactam will not be the panacea for CRE infections, with treatment failures still documented in approximately 30-50% of cases, particularly among those with CRE respiratory tract infections. [10] [11] [12] [13] Furthermore, the emergence of on-therapy ceftazidime-avibactam resistance 10 underscores the need for continued antibiotic innovation.
Developing truly novel antibiotics to match the diversity of beta-lactamases has proved challenging for scientists. An alternative strategy, exemplified by avibactam, is to protect the clinical utility of existing agents with novel inhibitors of the enzymes responsible for their degradation. Vaborbactam (VAB; formerly RPX7009) is a newly developed beta-lactamase inhibitor based on a cyclic boronic acid pharmacophore that was designed to specifically inhibit Ambler class A serine carbapenemases and potentiate the bactericidal activity of carbapenems against Enterobacteriaceae. 14 In 2014, VAB in combination with meropenem (MEM), was designated as a Qualified Infectious Disease Product by the U.S. Food and Drug Administration (FDA) for the treatment of complicated urinary tract infections (cUTIs) and acute pyelonephritis (AP), complicated intra-abdominal infections (cIAIs), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), febrile neutropenia, and catheter-related bloodstream infections. 15 The combination of MEM and VAB (MV) received FDA approval for the treatment of adults with cUTI and AP in August 2017. 16 The objective of this article is to review the available data pertaining to MV with emphasis on biochemistry, pharmacokinetic and pharmacodynamic (PK/PD) characteristics, in vitro activity against CRE, and current progress in clinical trials.
Data Sources
Literature searches of MEDLINE (1946 to November 2017) and EMBASE (1974-November 2017) were conducted using the search terms "vaborbactam," "meropenem and vaborbactam," and "RPX7009." Results were limited to articles available in English. Additional citations were identified from the references of relevant literature. Current trials focusing on MV were identified from clinicaltrials.gov. FDA review documents for the cUTI and AP indications were also examined. Last, data were obtained from conference proceedings and published abstracts.
Chemistry and Mechanism of Action

Meropenem
The carbapenem class of antibiotics have in common a carbon atom substituted for sulfur at position 1 and an unsaturated bond between C2 and C3 of the familiar penicillin nucleus (Figure 1) . 17 In addition, carbapenems contain a 6-hydroxyethyl side chain in which the hydrogens at C5 and C6 are in a trans orientation that confers stability to a wide variety of beta-lactamases. 17 MEM differs in structure from the early-generation carbapenem, imipenem, by the addition of a methyl group at C1 that imparts resistance to renal dehydropeptidase I (DHP-I). Therefore, co-administration with a DHP-I inhibitor, such as cilastatin, is unnecessary. The basic dimethylcarbamoylpyrrolidinethio side chain at C2 on MEM enhances activity against gram-negative organisms. 17, 18 Carbapenems exert their bactericidal effect through penicillin binding proteins (PBPs) with subsequent inhibition of cell wall synthesis. 18 In Enterobacteriaceae, both imipenem and MEM exhibit their highest affinity for PBP2, but they also bind effectively to PBP1a and PBP1b. 18 In addition, MEM binds to and inhibits PBP3, which results in filamentation of gram-negative baccilli. 18 The higher affinity of MEM for PBP2 in Pseudomonas aeruginosa is another differentiating feature compared with imipenem. 18 Like imipenem, MEM acts as an inducer for chromosomally mediated class C enzymes, although MEM appears to have a lower induction potential than imipenem. Despite induction, both antibiotics are highly active against most stably derepressed mutants. 18 The minimum inhibitory concentration (MIC) of MEM for clinical isolates of K. pneumoniae strains that produce extendedspectrum beta-lactamases (ESBL) are usually 8-to 16-fold lower than the MICs of imipenem. 19 Drug efflux and loss of porins are important mechanisms of bacterial resistance to both agents. 19 Carbapenems are unique among the beta-lactams for showing minimal inoculum effect. 18, 20 The stability of MEM to ESBLs and AmpC enzymes together with preserved activity in high inoculum infections suggests that MEM may provide a stronger antibiotic backbone compared to cephalosporins when co-formulated with carbapenemase inhibitors.
Vaborbactam
VAB is a novel non-beta-lactam boronic acid beta-lactamase inhibitor (Figure 1 ). 14 Boronic acids have been recognized as potent inhibitors of serine proteases for nearly 50 years. 21 In this regard, boronic acids are particularly attractive because the electron deficit boron atom acts as a strong electrophile with a high propensity to form covalent bonds with catalytic serine neutrophils. 21 The covalent adduct that forms between the active site serine of beta-lactamases and the boronate moiety mimics the tetrahedral transition state on the acylation/deacylation pathway, and binding results in rapid enzyme deactivation. 21 A unique feature of boronic acid inhibitors, in contrast to earlier-generation betalactamase inhibitors, which form irreversible acylenzyme intermediates that decompose through hydrolysis, is that the covalent bond is reversible, and VAB is not hydrolyzed during the course of the reaction. 14 The mechanism of avibactam is also covalent binding and, in most cases, reversible. 22 Although the avibactam mechanism of action involves ring opening, the ring is recycled after deacylation rather than hydrolyzed, resulting in regeneration of intact avibactam. The exception is KPC, which slowly desulfates avibactam creating inactive avibactam fragments. 22 Mechanistically, then, VAB may have an advantage in potentially being recycled to inhibit additional KPC enzymes.
In contrast to the boron-containing "core" interactions, which are largely conserved across a number of serine beta-lactamases, the region associated with binding the N-acyl substituent is variable across different enzymes. The thiophene moiety at this position on VAB, which is reminiscent of the R1 group in cefoxitin and cephalothin, is particularly suited to binding interactions with the KPC enzyme. The inclusion of the thiophene moiety resulted in an inhibitor that is 16-fold more potent than the simple Nacetyl analogue. 14, 21 The more potent inhibition 23 These observations underscore the importance of optimizing the activity of VAB by pairing it with a partner antimicrobial that is stable to ESBL and AmpC hydrolysis, such as MEM.
Pharmacokinetics
The PK parameters of MEM and VAB have been examined in phase 1 and 3 studies. [24] [25] [26] [27] In the first study to involve human subjects, researchers 24 evaluated the PK characteristics of VAB alone in 80 healthy volunteers. VAB was administered as single or multiple-ascending doses ranging from 250 mg to 2000 mg. Each dose was administered over 3 hours, and multiple-dose infusions were administered every 8 hours. VAB exposure increased proportionally with dose to a peak plasma concentration (Cmax) of 41.6 AE 4.75 mg/L and 40.9 AE 4.68 mg/L after single and multiple 2000-mg doses, respectively. No evidence of drug accumulation was demonstrated. The mean steadystate area under the concentration-time curve from 0 to 8 hours (AUC 0-8hr ) following 2000 mg was 145 AE 15.8 mg h/L with the corresponding plasma concentration-versus-time profile suggesting exposure in excess of 8 mg/L beyond 5 hours. 24 A second study evaluated the PK parameters of MEM and VAB alone and in combination in 80 healthy volunteers. 26 The two agents achieved similar plasma concentrations that did not change when co-administered compared with administration alone. 26 MEM is extensively distributed to most body fluids and tissues, including cerebrospinal fluid. 29 The only in-human MV distribution study published to date evaluated the PK characteristics of MV in epithelial lining fluid (ELF) and alveolar macrophages (AMs) in 26 healthy adults who received 2000 mg of both drugs IV every 8 hours over 3 hours for three doses. 25 Although controversy exists, antibiotic concentrations in ELF for extracellular pathogens and in AMs for intracellular pathogens are thought to be important for the treatment of bronchopulmonary infections. 30, 31 Based on mean AUC 0-8hr values in ELF and plasma, the intrapulmonary penetration of MEM and VAB were 0.63 and 0.53, respectively. 25 This estimate is increased to 0.79 when accounting for the plasma protein binding of VAB. 25 The penetration ratios of MEM and VAB are comparable to those of earlier beta-lactam agents that have been used successfully in lung infections but substantially lower than those of macrolides and fluoroquinolones, which are present in the ELF at 2-to 10-fold greater concentrations than in the plasma. 32 In agreement with previous studies involving betalactam antibiotics, 31 MEM concentrations in AMs were below the limit of detection (< 0.01 mg/ L). 25 Median concentrations of VAB in AMs ranged from 2.35 mg/L to 6.94 mg/L. 25 The clinical utility of the later observation as pertains to VAB activity against intracellular pathogens is uncertain because VAB has not demonstrated bactericidal activity alone. 14 
Metabolism and Excretion
Renal excretion of unchanged drug is the primary route of elimination for both MEM and VAB. 24, 27, 29 Up to 70% of an administered dose of MEM is excreted unchanged in the urine with a further 20-25% recovered as the microbiologically inactive open lactam metabolite. 29 Extra renal metabolism of MEM can increase to 50% of the dose in patients with creatinine clearance (CrCl) < 20 ml/min. 29 Approximately 80-90% of the dose of VAB was recovered unchanged in the urine in healthy volunteers over 24-48 hours following a single dose; renal clearance does not change with repeated dosing in normal renal function. 24 VAB is not metabolized in vivo. 27 In healthy subjects, the steady-state elimination half-lives (T ½) for VAB and MEM ranged from 1.17 AE 0. 15 27 The T ½ of MEM and VAB were prolonged to 5.7 hours and 11.7 hours, respectively, in subjects with severe renal impairment (eGFR < 30 ml/min/1.73 m 2 ). VAB exposure also increased to a greater degree than MEM exposure in subjects with severe renal impairment and in those with ESRD on or off HD. Compared to subjects with normal renal function, the AUC 0-inf in subjects with severe renal impairment increased approximately 4.5-and 8-fold for MEM and VAB, respectively. Approximately 38% of a single dose of MEM and 53% of a single dose of VAB are removed during HD. In ESRD patients maintained on HD, MEM exposure (AUC 0-inf ) is increased approximately 3-fold when administered within 2 hours before HD and 7-fold when administered after HD. The corresponding changes in VAB exposure were substantially higher (10-fold before HD; 38-fold after HD). 27 These data indicate that the proportional dose adjustments dictated by the fixed combination product in patients with severe renal impairment and ESRD (Table 1) 16 will result in a higher systemic exposure ratio of VAB:MEM, particularly in HD patients. The clinical implications of these differences are unknown, although as discussed in the Safety section of this review, a higher proportion of subjects experienced adverse effects when MV was administered after HD compared to administration before. 27 PK data pertaining to patients receiving peritoneal dialysis or continuous renal replacement therapy have not been reported to date.
Population Pharmacokinetics
Population PK models for MEM and VAB were constructed using pooled data from healthy volunteers in phase 1 studies and patients enrolled in phase 3 studies. 26 The PK analysis population included adults across the lifespan (18-92 years of age) with body weights ranging from 40 kg to 177 kg and renal function ranging from 7.8 to 241 ml/min/1.73 m 2 eGFR. 26 The final model for both drugs was a two-compartment model with first-order elimination. Key covariate relationships identified included the following: (1) MEM and VAB clearance (CL) increased with increasing eGFR in a sigmoidal fashion with time varying eGFR; (2) MEM CL decreased with increasing age; (3) VAB CL increased with increasing height and was higher in healthy volunteers versus patients; (4) MEM central and peripheral compartment volume of distributions (Vc, Vp) increased with increasing body weight; and (5) VAB Vc increased with increasing body surface area and was higher in patients versus volunteers while Vp was higher in volunteers versus patients. 26 These findings indicate that body size, age, and infection status may affect the PK of MEM and VAB differentially, the clinical implications of which remain Table 2 . 27 Microbiological Spectrum of Activity
The activity of MV has been evaluated against a diverse range of surveillance and clinical isolates. [33] [34] [35] Tables 3 and 4 summarize the in vitro susceptibility data of gram-negative bacteria to MEM alone and in combination with VAB. The FDA set the minimum inhibitory concentration (MIC) susceptibility breakpoint for MV against Enterobacteriaceae at
16 This is notably higher than that of MEM as a single agent (MIC susceptibility breakpoint ≤ 1 mg/L) 36 and reflects the increased MEM exposure with the approved MV dosing regimen in addition to the contribution of VAB in optimizing the activity of MEM. 37 It must be noted also that the approved FDA breakpoint for MV gives a conservative estimate of activity. As discussed in the Pharmacodynamics section of this review, a dosage regimen of MEM 2000 mg plus VAB 2000 mg infused over 3 hours every 8 hours is predicted to produce exposures sufficient to be efficacious against strains with MICs as high as 8 mg/L for MEM when tested in the presence VAB 8 mg/L. 38, 39 Extrapolating the MV breakpoint interpretive criteria to recent surveillance studies, nearly all tested Enterobacteriaceae isolates have MICs within the susceptible range, including carbapenem-resistant phenotypes. [33] [34] [35] 37 In a recent study that included 133 multidrug-resistant carbapenemase-producing clinical isolates of Enterobacteriaceae, inclusive of Escherichia coli, K. pneumoniae, and Enterobacter spp., collected from 11 New York City hospitals, 98.5% (131/ 133) were inhibited by MEM ≤ 1 mg/L in the presence of VAB 8 mg/L. 33 Similar susceptibility rates for a genetically diverse contemporary global collection of 315 Enterobacteriaceae strains producing serine carbapenemases were observed for MV. 34 MEM activity was at least 64-fold greater against these isolates in the presence of VAB 8 mg/L, and 97.8% of isolates were inhibited by MEM ≤ 4 mg/L. 34 A large global surveillance study of > 14,000 clinical Gram-negative isolates collected during 2014 demonstrated that MV inhibited 99.5% of the > 10,000 Enterobacteriaceae isolates tested at ≤ 4 mg/L MEM in the presence of VAB 8 mg/ L. 35 Among resistant phenotypes of CRE, MV inhibited 79.6% at MEM ≤ 4 mg/L. Genes encoding MBLs and OXA-48 were detected in 15.5% and 10.2% of these isolates, respectively, accounting for the lower susceptibility rates than those documented in studies including only KPC-producing CRE. 35 As with other beta-lactamase inhibitors that are clinically available or in late stage development, VAB does not inhibit class B metallo-beta-lactamases (IMP, NDM, VIM). VAB also shows limited activity against class D carbapenemases (OXA-48 and its variants). 37 Among the KPC-CRE isolates (n=135) in the global surveillance study, however, 99.3% were inhibited at MEM ≤ 4 mg/ml and 100% at 8 mg/ml in the presence of VAB 8 mg/L. 35 In contrast to ceftazidime-avibactam, which displays higher MICs against KPC-3-compared to KPC-2-producing strains, MV has similar activity against strains producing either enzyme. 23 These observations are consistent with the previously described biochemistry of ceftazidime and MEM hydrolysis. Ceftazidime hydrolysis is 10-fold more efficient with KPC-3 versus KPC-2, while there is no difference in KPC-2 and KPC-3 hydrolysis of MEM, again suggesting MEM may be a more stable companion antibiotic. 23 The activity of MV against K. pneumoniae isolates characterized for mechanisms of resistance has been examined in two recent studies. 33, 34 In the first, isolates were screened for the presence of blaKPC, blaSHV, and blaTEM, the porin genes ompK35 and ompK36, and the efflux system gene acrB. 33 Among all KPC positive isolates, MEM MICs ranged from 0.008 mg/L to 2 mg/L in the presence of VAB 8 mg/L. Interestingly, there was no correlation between MV MICs and relative expression level of blaKPC, ompK36, or acrB (most isolates were ompK35 deficient), although the two isolates with the highest MV MICs had decreased expression of ompK36 compared to only 1 of 10 isolates with an MEM MIC ≤ 0.5 mg/L (p=0.046). 33 The second study examined the activity of MV against KPC-producing K. pneumoniae isolates carrying additional broad-spectrum beta-lactamases, such as ESBLs or derepressed intrinsic enzymes (OXA or AmpC). 34 MEM combined with VAB at a fixed concentration of 8 mg/L demonstrated 32-to > 1067-fold reductions in MIC 90 with MIC 90 ranging from ≤ 0.06 mg/L to 2 mg/L. 34 As noted previously, VAB is a less potent inhibitor of ESBL and class C beta-lactamases compared to KPC. In a series of in vitro experiments aimed at fully characterizing the spectrum of inhibition of VAB, researchers tested the ESBLliable agents, ceftazidime and aztreonam, alone and in combination with VAB (4 mg/L), tazobactam, or clavulanate. 23 VAB restored ceftazidime and aztreonam activity against CTX-M-and AmpC-producing strains with a potency similar to the comparator beta-lactamase inhibitors; however, it was generally less potent than comparators against SHV and TEM producers. 23 The difference in potency is thought to be due to slower dissociation of the VAB-KPC complex compared to complexes with other enzymes (residence time 992 minutes for KPC-2 vs 19 minutes and 3 minutes for CTX-M-15 and AmpC, respectively). 23 In the case of SHV-and TEM-producing strains, VAB exhibited "fast-onfast-off" behavior, suggesting the low potency of VAB is driven by the inability to form stable inhibitory complexes with these enzymes. 23 These observations are of relevance because CRE rarely produce KPC alone, with most strains simultaneously producing other broad-spectrum beta-lactamases. 3 However, because MEM is inactivated by KPC but not most other beta-lactamases, the co-formulation of MEM and VAB should provide reliable broad-spectrum activity against strains producing multiple beta-lactamases. 23 In contrast to the effect of VAB on the susceptibility of Enterobacteriaceae to MEM (Table 4) , VAB did not improve activity of MEM against P. aeruginosa or Acinetobacter baumannii, likely due to alternative mechanisms of resistance including the production of class B and D carbapenemases as well as porin alterations and drug efflux. 33, 35 In the past, there has been a several-year lag between antimicrobial launch and access to an FDA-cleared commercial antimicrobial susceptibility testing device. 40 The
Pharmacodynamics
Consideration of PD principles when designing antimicrobial dosage regimens for the treatment of infections caused by MDR pathogens is an essential component for clinical and microbiological success. Attaining PD targets associated with suppression of drug resistance is also an important consideration in the current era. Accordingly, the MV dosing regimen advanced to phase 3 trials was designed to ensure adequate exposure in patients infected with pathogens with MIC values bracketing the susceptibility threshold, as well as suppress resistance development in KPC-producing Enterobacteriaceae. 41 Previous literature pertaining to the PK/PD of MEM alone, phase 1 PK studies of MV in healthy volunteers, MV resistance development studies, in vitro hollow-fiber PD model experiments, and murine thigh and lung infection model studies were used to inform the optimal dosing regimen. 24, 39, [41] [42] [43] [44] The PDs of MEM have been well characterized and, like other beta-lactam antibiotics, the PK/PD parameter best correlated with antimicrobial activity is the percentage of the dosing interval that the free drug concentration remains above the MIC of the infecting organism (%f T > MIC). 42 For gram-negative bacteria, bacteriostatic and bactericidal responses are observed when the MEM concentration remains above the MIC for approximately 20-30% and 40-50% of the dosing interval, respectively. 42 To optimize the probability of target attainment, extended infusions of MEM have been evaluated in a number of studies using population PK modelling and Monte Carlo simulations. 42, 45, 46 In these studies, a dosage regimen of MEM 2000 mg IV administered over 3 hours every 8 hours demonstrated high probability of bactericidal plasma exposure at an MIC 8 mg/L, which is considered resistant by CLSI interpretive criteria. 36, 42, 45, 46 The PK/PD indices widely used to guide the design of dosing regimens, such as %fT > MIC or the C max :MIC ratio for concentration-dependent antibiotics, may not be directly applicable to betalactamase inhibitors because, like VAB, most lack intrinsic antibacterial activity. 14, 47 Instead, factors that determine the success of inhibitors include inhibitory activity (quantified as the I 50 value), quantity of beta-lactamase produced, organism tested, infection-site conditions, and the partner beta-lactam. 48 A series of standard in vitro susceptibility studies evaluated the activity of MEM alone and in combination with various concentrations of VAB against bacterial isolates previously characterized for the presence of resistance determinants. The inhibitory activity of VAB was concentration dependent with concentrations of 4 mg/L to 8 mg/L consistently restoring the activity of MEM against Enterobacteriaceae strains producing KPC with or without coexpression of ESBL and AmpC beta-lactamases. Negligible improvements occurred with higher VAB concentrations of 16 mg/L and 32 mg/L. 41 To further inform optimal MV exposure, the concentrations of each agent required to prevent resistance development among KPC-producing K. pneumoniae was examined in a single-step resistance selection study. 49 With VAB 4 mg/L, the observed resistance frequencies were low (< 1 9 10 À8 to 2.8 9 10
À6
), but resistance development was prevented in all isolates (resistance frequency < 1 9 10
À9
) when tested at fixed concentrations of 8 mg/L for both agents. 49 The activity of various concentrations of MV against KPC-producing Enterobacteriaceae, many of which also co-produced ESBL and/or hyper-produced AmpC beta-lactamases, was further examined in a series of in vitro studies utilizing hollow-fiber PD models. 39 Experiments using concentrations simulating human exposures of MEM 1000 mg and VAB 1000 mg infused over 3 hours every 8 hours produced > 4 log 10 colony forming units (CFU)/ml reduction in bacterial burden over the course of the 32-hour experiment in isolates with MV MICs < 1 mg/L (in the presence of VAB 8 mg/L). One isolate, however, with an MV MIC of 1 mg/L, showed significant regrowth at 16 hours and development of resistance (postexposure MV MIC ≥ 32 mg/L). Higher Similar MV PD studies were conducted using neutropenic murine thigh and lung infection models. 44 KPC-producing Enterobacteriaceae isolates with outer membrane porin mutations and MEM MICs between 8 mg/L and 512 mg/L were used. Both MEM and VAB were administered to mice to produce exposure equivalent to 2000 mg infused over 3 hours every 8 hours in humans. At these exposure levels, MV was bactericidal against all isolates tested, including one isolate with an MV MIC value of 8 mg/L.
The findings of these studies suggest that the dosage regimen of MEM 2000 mg plus VAB 2000 mg every 8 hours by a 3-hour infusion will be effective against Enterobacteriaceae strains with MV MIC values of up to 8 mg/L. Although clinical correlation is required, available in vitro data should reassure clinicians when using this agent for infections by pathogens with MIC values near the FDA susceptibility breakpoint. 16, 39, 44 Resistance In addition to limited activity against CRE-producing class B or class D beta-lactamases, KPCproducing Enterobacteriaceae with relatively high MEM MICs despite the presence of VAB 8 mg/L have been observed in the laboratory and in surveillance studies. [33] [34] [35] Although beta-lactamase production is a predominant mechanism of carbapenem-resistance among Enterobacteriaceae, porin down-regulation/loss-of-function and efflux system overexpression are other well-documented mechanisms of elevated carbapenem MICs that can be selected for during carbapenem therapy. 50, 51 One group conducted a series of experiments aimed at characterizing mechanisms responsible for observed MV MIC elevations in KPC-producing K. pneumoniae mutants selected in vitro using suboptimal MV exposures. They determined that the majority of resistant phenotypes were associated with inactivation of ompK36 due to various insertions, deletions, stop mutations, or substitutions. 49 Changes in expression of blaKPC or efflux pump genes were not identified in mutants with the resistant phenotype without ompK36 mutations. In addition, comparison of other porin gene sequences that have been implicated in carbapenem resistance did not identify mutations, and the resistance mechanism(s) in these isolates is the subject of ongoing analysis. Notably, porin mutations did not arise when isolates were exposed to 8 mg/ml concentrations of both drugs. 49 It is important to appreciate, however, that although these fixed concentrations prevented in vitro resistance selection at the site of infection, bacteria are likely to be exposed to changing VAB concentrations and changing MEM:VAB concentrations ratios, and these differences may modulate development of resistance. The turnover values (the number of molecules required to inhibit a single enzyme) for both VAB and avibactam against KPC have consistently been shown to be 1. 37, 52 Thus, the 1:1 ratio of MEM to VAB in the fixed-dose formulation 16 compared to that of ceftazidime-avibactam (4:1) 53 may be more likely to preserve activity in the setting of in vivo PK/PD variability.
The role of decreased permeability and efflux in elevated MV MICs has also been documented by other investigators in susceptibility studies of clinical isolates. Castanheira et al. characterized intrinsic mechanisms associated with MEM MICs ≥ 16 mg/L in the presence of VAB 8 mg/L for seven clinical KPC-producing K. pneumoniae. 34 Four of these isolates carried a metallobeta-lactamase gene (VIM-1 and VIM-4) along with blaKPC, and MV resistance is therefore not unexpected. The remaining three isolates showed reduced expression of ompK37 and modest to high efflux system expression. Lapuebla et al. 33 observed that MV MICs were relatively unaffected by increased expression of blaKPC or acrB or diminished ompK35 alone. However, MICs were increased in isolates with concomitantly diminished ompK35 and ompK36 expression and increased blaKPC expression, although the effect was attenuated with higher VAB concentrations. 33 These observations are consistent with experiments demonstrating that, like carbapenems, VAB is able to cross the outer membrane of K. pneumoniae using both ompK35 and ompK36. 23 Unlike carbapenems, however, which generally do not display a change in MIC with loss-of-function of ompK35 or ompK36 individually, ompK36 inactivation is associated with a larger effect on MV MICs compared to ompK35 inactivation, indicating that ompK36 may be the preferred porin for VAB uptake. 23 Amino acid duplications or insertions in the conserved L3 loop of ompK36 have been identified in variants with increased MV MICs. This loop folds back into the porin channel, determining channel size and represents the bottleneck for carbapenems and likely VAB diffusion. 54 Of note, unlike resistant ceftazidimeavibactam isolates, 10 no new allelic forms of KPC with reduced sensitivity to inhibition by VAB have been identified to date. 37 In the phase 3 clinical study evaluating MV for the treatment of cUTI, three patients with baseline urine cultures positive for K. pneumoniae treated with MV in the TANGO-1 study had follow-up isolates with ≥ 4-fold increases in MIC to MV relative to baseline. The increases were observed between 10 and 19 days following MV initiation and all remained in the susceptible range. A number of changes appeared to be involved in the MIC elevations, including higher efflux operon expression, loss-of-function mutation in ompK35 and ompK36, and increases in the beta-lactamase copy number (CTX-M-15, TEM-1, OXA-1, SHV-1, and CMY-4). 37 Notably, on a background of fully functional ompK35 and ompK36 porins but increased efflux and a number of preexisting beta-lactamases, a 2-fold increase in CTX-M-15 copy number was sufficient to cause a 4-fold increase in the MIC of MV. 37 This suggests that the differential potency of VAB against KPC and ESBLs may impact on activity even with a companion antibiotic that is generally stable to ESBLs. In a recent presentation of the TANGO-2 study, one of 25 patients treated with MV for a KPC-producing Enterobacteriaceae infection had a subsequent isolate with a 4-fold increase in MIC after 6 days of therapy. 55 Similar to the trend observed in TANGO-1, however, the follow-up isolate remained susceptible to MV (MIC 0.25 mg/L increased to 1 mg/L). The MIC increase was associated with higher efflux operon expression but no blaKPC target-site mutations. Four patients with a KPC-producing Enterobacteriaceae infection were treated with ceftazidimeavibactam at the time of this analysis, and one had a follow-up isolate with > 128-fold increase in MIC (0.5 mg/L to > 64 mg/L) following 7 days of therapy. Resistance was associated with a previously described blaKPC point mutation, increased blaKPC expression, porin down regulation, and increased efflux. 55 In vitro resistance development studies using ceftazidime-avibactam as the selective agent have identified several mutations to the omega loop of KPC, which result in increased ceftazidime hydrolysis and consequent ceftazidime-avibactam resistance. 56 The tyrosine for aspartic acid at position 179 (D179Y) variant in particular was identified in TANGO-2 and recovered from patients treated with ceftazidime-avibactam in an earlier case series. 55, 57, 58 The phenotype associated with this mutation is notable for restoration of MEM susceptibility as well as decreased MICs to other beta-lactam antibiotics. [56] [57] [58] MEM resistance has reemerged in vitro following, albeit pro-longed, passage at subinhibitory MEM concentrations, however. 59 In a series of experiments, 41 the effect was evaluated of the D179Y mutation on the interactions of VAB and avibactam with the KPC-2 and KPC-3 enzymes. When ceftazidime activity was tested in the presence of avibactam (4 mg/L) or VAB (8 mg/L) against wild-type KPC-2-and KPC-3-producing isolates, MICs were similar (0.5-1 mg/L). As expected, when ceftazidime-avibactam was tested against D179Y variants, the ceftazidime MICs increased 5-to 6-fold. When the combination of ceftazidime and VAB (8 mg/L) was tested against the D179Y variants, MIC increases were less pronounced (2-to 3-fold) and remained at or below the current CLSI ceftazidime clinical breakpoint of 4 mg/L. 36 Evaluation of kinetic parameters of ceftazidime hydrolysis inhibition by wild type and D179Y variants corroborate these findings with Ki increasing 30-fold for avibactam versus < 3-fold for VAB against the D179Y variant. While these experiments suggest VAB maintains useful inhibitory activity against blaKPC target-based mutations resulting in increased ceftazidime hydrolysis, ceftazidime-avibactam resistance has been associated with a number of mechanisms including porin inactivation, efflux system over-expression, and increased blaKPC expression, to which MV may also be vulnerable. 55, [60] [61] [62] Thus testing for MV susceptibility will be an important step to inform treatment decisions.
Clinical Efficacy Data
In recognition of the urgent need to bring effective anti-CRE agents to the clinic, the development program for MV proceeded directly 454 PHARMACOTHERAPY Volume 38, Number 4, 2018 from preclinical studies to phase 3 clinical trials.
The established efficacy and safety of MEM together with promising in vitro, animal, and preclinical PK data for VAB alone and in combination with MEM allowed for this fast track development timeline. 63 Two phase 3 studies were initiated in 2014 to evaluate the clinical efficacy and safety of MV. One was an indication-focused trial to support regulatory approvals, and the second was a pathogenfocused trial to provide important data in patients with target pathogens (i.e., CRE). 63 The Targeting Antibiotic Non-susceptible Gram-Negative Organisms (TANGO)-1 trial was a multicenter, double-blind, randomized, noninferiority study comparing MV to piperacillintazobactam (TZP) in patients with cUTI and AP, predominately due to carbapenem susceptible pathogens. 63 Adult patients with a diagnosis of cUTI or AP warranting treatment with at least 5 days of IV antibiotics were randomized 1:1 to receive either MEM 2000 mg plus VAB 2000 mg IV administered over 3 hours every 8 hours or TZP 4500 mg IV administered as a standard infusion over 30 minutes every 8 hours for 10 days (or 14 days for patients with bacteremia). 63 Patients could be switched to oral levofloxacin following a minimum of 15 doses of study drug if they met prespecified criteria. Alternative oral antibiotics were permitted in patients with levofloxacin-resistant isolates. Key exclusion criteria included baseline CrCl < 30 ml/min calculated with the Cockroft-Gault formula, immunosuppression, hepatic disease, severe sepsis, history of seizure disorder, prior treatment with valproic acid, and pregnancy or breast-feeding. 63 The primary efficacy outcome was a composite end point -overall response -defined as clinical cure or improvement and microbiological eradication (or in some cases presumed eradication based on clinical response). Response was evaluated in the microbiologic modified intent-to-treat population (mMITT) composed of all patients who received at least one dose of study drug and had at least one baseline pathogen on urine culture. Overall response was assessed at the end of IV treatment (EOIVT; days 5-10) for the primary end point. 63 A total of 545 patients were randomized and received at least one dose of assigned antibiotic, and 68% (n=374) were included in the mMITT population. Baseline demographic characteristics were well balanced between treatment groups. Patients were predominantly female (66%), and the mean age was 52.8 years; 15.6% were ≥ 75 years. The majority of study sites were in the Eastern European region, and therefore African American, Hispanic, and Asian patients were underrepresented. Most patients had AP (59%), and the remaining patients had cUTI with a removable source (22%) or cUTI with a nonremovable source (19%). Blood cultures were positive in 7% of the mMITT population. Less than one-third (31%) of patients presented with the systemic inflammatory response syndrome (SIRS). 63 The median Charlson Comorbidity Index score was 1 in patients with AP and 4 in patients with cUTI. Approximately 16% of patients had diabetes mellitus. The CrCl was > 50 ml/min in the majority of patients (88%). 64 Overall infection severity and rates of underlying comorbidities were lower than in typical hospitalized cUTI patients. 64 In particular, preexisting renal impairment is common in older patients prone to cUTI, and thus it is disappointing that MV efficacy and safety data were not evaluated in this important subset of patients in this study.
E. coli was the predominant uropathogen (65%), followed by K. pneumoniae (16%), Enterococcus faecalis (7%), Proteus mirabilis (5%), E. cloacae (4%), and P. aeruginosa (4%). Among Enterobacteriaceae isolates (n=352), the MIC 90 for MV and TZP were ≤ 0.06 mg/L and > 64 mg/L, respectively. Approximately 30% of isolates expressed class A ESBLs, class D betalactamases, AmpC enzymes, and/or carbapenemases. 65 Fifteen percent of Enterobacteriaceae were resistant to TZP at baseline, 63 which is in line with resistance rates in many regions 66 but also suggests it may not have been an ideal comparator agent.
One of the major limitations of the TANGO-1 trial was that few infections were caused by CRE, which hinders the evaluation of the contribution of VAB to the effectiveness of MV. Carbapenemase enzymes were identified in five Enterobacteriaceae (three KPC-2, one OXA-48, and one VIM-1). MV resistance was observed in one K. pneumoniae isolate carrying OXA-48 (MIC 32 mg/L). The three KPC-2-producing isolates had MV MICs of ≤ 0.06 mg/L (Provedentia stuartii) and ≤ 0.06 mg/L and 2 mg/ L (K. pneumoniae). The VIM-1-producing P. mirabilis had an MV MIC of 0.5 mg/L. Resistance to MV was relatively high among the few P. aeruginosa strains that were isolated (MV 6/14). 37 Overall success at the EOIVT time point was achieved in a high proportion of patients in both treatment groups (MV 98.4% vs TZP 94%; 95% confidence interval [CI], 0.7-9.1%). 63 The 4.5% treatment difference met the prespecified noninferiority margin as well as criteria for superiority. All failures at EOIVT in the MV group (n=3) were secondary to adverse events (infusionrelated reactions). In the TZP group, failures were due to adverse events (n=4), withdrawal of consent (n=1), and microbiological persistence or recurrence (n=3). Overall response at the test of cure time-point (TOC; days 15-19) was considerably lower in both groups compared to the earlier assessment, but success remained numerically higher for the MV group (74.5% vs 70.3%; 95% CI, 4.9-13.2%). Lower overall success in both groups at TOC was driven by lower microbiological eradication rates (68.8% vs 62.1%; 95% CI, 3.0-16.2%). 63 Lower microbiological eradication at later time points was also observed in two recent trials comparing novel beta-lactamase inhibitor combinations in cUTI and likely reflects the high incidence of asymptomatic bacteriuria encountered in patients with underlying urinary tract abnormalities. 67, 68 Indeed, the importance of source control is underscored by the observation that only approximately half of patients with a nonremovable source of infection achieved microbial eradication at TOC in the TANGO-1 trial (MV 51.4% vs TZP 53.5%; 95% CI, 23.5-19.4%). 64 Clinical cure and microbiological eradication rates for subgroups defined by age, gender, diabetes status, Charlson Comorbidity Index, and geographic region were consistent with the overall results. 64 There were too few patients with renal impairment to draw meaningful conclusions about therapeutic effect in this subgroup.
As discussed in the Resistance section of this review, MV MIC increases ≥ 4-fold from baseline were observed during or following treatment among three patients in the MV group (all K. pneumoniae) and four patients in the TZP group (one P. mirabilis and three P. aeruginosa). The three patients with K. pneumonia MIC increases who were treated with MV had overall success at the EOIVT. At the later TOC time point, one patient was assessed as indeterminate and the remaining two patients experienced microbiological recurrence. 64 Overall success was observed at EOIVT for all three patients with CRE isolates in the MV group. Two patients, one with OXA-48-producing K. pneumoniae and the other with VIM-1-producing P. mirabilis, achieved overall success at TOC. The outcome in the remaining patient (KPC-2-producing P. stuartii) was indeterminate at TOC. 63 It is difficult to draw meaningful conclusions about the clinical effectiveness of MV for CRE infections from this small number of patients.
The most anticipated phase 3 study is TANGO-2, a multicenter, randomized, openlabel trial evaluating the safety and efficacy of MV monotherapy versus best available therapy (BAT) in patients with confirmed or suspected CRE infections (cUTI and AP, bacteremia, HAP, VAP, and cIAIs). 69 As noted by regulators and clinical investigators, a number of methodological issues complicate the study of CRE infections. 70, 71 Patients with CRE infections typically present with substantial comorbidity and a high degree of index severity, which renders most ineligible for enrollment in typical registry trials of novel antimicrobials. 6 Furthermore, the lack of a clear consensus in the preferred treatment strategy for CRE infections leaves no standard basis for comparison. Recognizing the potential challenges in conducting a trial such as TANGO-2, investigators first performed a retrospective analysis of > 250 patients with CRE infections from centers in the United States and Europe. The objective was to gain additional insight into the clinical characteristics of this patient population and then evaluate contemporary treatment strategies and associated outcomes. 6 This analysis was used to inform the TANGO-2 protocol design especially pertaining to inclusion and exclusion criteria. As a result, patients who were immunocompromised, had renal insufficiency (including need for dialysis), or had severe sepsis were eligible for enrollment in TANGO-2. 6 Furthermore, no consensus in the preferred therapy emerged, and thus the TANGO-2 BAT arm allowed for a wide variety of monotherapy and combination regimens (carbapenems, aminoglycosides, polymixins, and tigecycline). 69 Ceftazidime-avibactam, as monotherapy only, was also permitted. The monotherapy restriction for ceftazidime-avibactam is notable because case series have documented a second antimicrobial is used in approximately 30-65% of patients. [10] [11] [12] [13] A preliminary subgroup analysis has recently been presented for 72 enrolled patients, including 43 with confirmed CRE infections (86% KPC). As anticipated, a large portion of patients were elderly (47% ≥ 65 years) and had multiple comorbidities (51% Charlson Comorbidity Index 456 PHARMACOTHERAPY Volume 38, Number 4, 2018 > 6), and > 40% were immunocompromised. Further, one-third of patients randomized to the MV arm had experienced prior treatment failure. Among patients assigned to the BAT arm, most (73%) were treated with combination therapy that included up to four antibiotics. 72 Surprisingly, only four patients with KPC infections received ceftazidime-avibactam monotherapy. 55 The most common infection was bacteremia (47%), followed by cUTI/AP (35%) and HAP/ VAP (12%). The clinical cure rate (complete resolution of signs and symptoms) for CRE infections was significantly higher in patients assigned to MV (57% vs 27%; p=0.04). 72 In addition, 28-day mortality trended lower in the MV group (18% vs 33%; p=0.27). Results were consistent across all sites of infection and among immunocompromised patients. 73, 74 Importantly, MV appeared to perform well among patients with HAP/VAP or bacteremia (28-day mortality 4/16, 25% vs 4/9, 44%). 72, 74 Based on the findings of this interim analysis, an independent Data and Safety Monitoring Board recommended terminating randomization of additional patients to the BAT group in late July 2017. Patients will continue to be enrolled in the MV arm at selected sites moving forward. 75 In addition to TANGO-1 and TANGO-2, a study evaluating the PK, efficacy, and safety of MV in pediatric patients is currently under way (NCT02687906), and a phase 3b study in patients with HAP/VAP is planned for the near future (TANGO-3; NCT03006679).
Safety and Tolerability
To date, the safety and tolerability of MV have been evaluated in 407 patients who were treated with varying doses in two phase 3 trials (295 patients) and three phase 1 trials (112 subjects). 24, 25, 64 Where described, assessment was conducted by physical examination, laboratory tests, vital sign monitoring, ECG monitoring, and recording of treatment-emergent adverse events (TEAEs). 24, 25, 64 In the first-in-human dose-ranging PK study of VAB alone, TEAEs occurring in > 10% of VAB treated subjects included infusion site phlebitis (42%), headache (29%), catheter site pain, hematoma or phlebitis (13-29%), lethargy (21%), and contact dermatitis (13%). 24 All TEAEs were similar in incidence and severity to the placebo group. There was no evidence to suggest the incidence or severity of TEAEs increased with higher VAB doses with the exception of lethargy, which was observed more frequently (67%) in the multiple 2000-mg dose cohort compared to 0%, 17%, and 0% in the multiple 250-mg, 1000-mg, and 1500-mg dose cohorts, respectively. 24 Safety as assessed by clinical laboratory tests, vital signs, and ECG monitoring did not reveal any signals for concern. 24 In the single-dose renal impairment study (Study 504), 14 subjects (34%) reported at least one TEAE. 64 The most frequently reported TEAEs were diarrhea, headache, abdominal pain, and contact dermatitis. Similar proportions of subjects reported TEAEs by renal function group. In contrast, a higher proportion of subjects reported TEAEs when MV was administered after dialysis (62.5%) compared to administration before dialysis (22.2%). The type and severity of TEAEs were similar to those reported among subjects in other renal function groups, however. 64 Detailed safety outcomes from TANGO-1 were reported in the sponsor's FDA submission. 64 TEAEs occurred in 39% and 36% of patients in the MV and TZP arms, respectively. Approximately 40% were deemed to be related to the study drug, and most were of mild to moderate severity. Few patients (2.9% and 5.1%, respectively) discontinued the study drug due to adverse events (AEs). 64 The most common AEs in the MV versus TZP groups were headache (8.8% vs 4.4%), diarrhea (3.3% vs 4.4%), infusion-related reaction/phlebitis (4.4% vs 0.7%), nausea (1.8% vs 1.5%), and elevated hepatic enzymes (alanine aminotransferase 1.8% vs 0.4%; aspartate aminotransferase 1.5% vs 0.7%), respectively.
16 Serious adverse effects (SAEs) occurred in 11 (4%) and 12 (4.4%) patients in the MV and TZP groups, respectively. Two patients in each group died. The causes of death in the MV group were aspiration pneumonia and sudden cardiac arrest; neither were deemed to be related to study drug administration. 64 AEs of special interest based on the known safety profile of MEM include Clostridium difficile-associated diarrhea (CDAD), hypersensitivity reactions, and seizures.
VAB has no antimicrobial activity alone, and it has shown little or no potentiation of biapenem against anaerobes, 76 but the impact of VAB in combination with MEM on bowel flora is unknown at this time. In TANGO-1, CDAD was not reported in any patients treated with MV; 64 however, patients in this trial composed a low-risk population based on age and burden of comorbidity as well as exclusion of those with severe renal impairment and immunosuppression. Among the higher risk study population in the TANGO-2 study, CDAD was reported in one patient in the MV group and two patients in the BAT group. 64 Considering that the vast majority of patients in the BAT arm received an aminoglycoside and/or a polymyxin, it is perhaps not unexpected that nephrotoxicity was lower in patients in the MV groups (11% vs 24%; p value not reported). 72 The proportion of patients with hypersensitivity reactions in the pooled phase 1 and phase 3 studies was similar in the MV and comparator groups (11/407, 2.7% vs 7/338, 2.1%, respectively). Hypersensitivity reactions led to the discontinuation of MV in four patients. Two of these patients had a severe or life-threatening infusion-related reactions. 64 There is an increased risk of seizures associated with the carbapenem class of antibiotics, particularly imipenem. Animal studies suggest MEM is less likely than imipenem to cause neurotoxicity, 77, 78 and higher than standard MEM doses in pediatric patients with bacterial meningitis have demonstrated a low overall incidence of seizures. 79 The neurotoxic potential associated with high-dose, prolonged infusion MEM in adults is unknown. Seizures were not reported for any patient treated with MV in phase 1 studies or in the TANGO-1 trial. One patient in TANGO-1 developed "generalized tremor" and headache during the ninth infusion of MV, leading to study drug withdrawal. 64 Patients with a history of epilepsy or known seizure disorder were excluded from phase 1 studies as well as TANGO-1. Furthermore, moderate to severe renal impairment is a well-documented risk factor for carbapenem-associated seizures, 79 and these patients have been underrepresented in completed studies.
A unique concern pertaining to the use of serine beta-lactamase inhibitors is their potential to interact with human serine proteases in vivo. 14 Reassuringly, when tested against a panel of common mammalian serine proteases, VAB IC 50 values (the inhibitor concentration required to achieve 50% inhibition of enzyme activity) were ≥ 1000 µmol/L.
14 It is surmised that this selectivity is secondary to the cyclic boronic structure, which is a poor substrate for the more sterically hindered mammalian serine proteases that act exclusively on linear substrates. 14 Limited data pertaining to MV drug interactions are available. Based on in vitro and in vivo data, VAB appears to have a low potential for clinically important drug interactions. 27 VAB does not undergo hepatic metabolism and at clinically relevant concentrations, it does not inhibit the cytochrome P450 isoenzymes, renal transporters, or hepatic transporters. VAB showed no potential for in vitro induction of CYP1A2, CYP2B6, and CYP3A4. 27 Previously described interactions between MEM and agents, such as valproic acid and probenecid, 17, 18 would be expected to occur with the co-formulated product.
To summarize, the data available to date have not demonstrated significant safety concerns for MV. However, assessment of safety is limited by the small number of healthy subjects and patients to whom it has been administered. Exclusion criteria in TANGO-1 also limit the generalizability of safety findings to the patients likely to receive MV in the clinic, that is, those with infectionrelated or preexisting organ dysfunction, compromised immune function, and substantial burden of baseline comorbidity. An accurate safety assessment will require full review of data from the TANGO-2 study in addition to postmarketing surveillance and real-world data.
Future Directions and Conclusions
Carbapenem antibiotics have traditionally fulfilled a critical role in the treatment of serious bacterial infections due to MDR pathogens. The increasing prevalence of CRE therefore represents an urgent public health threat. 1 The high morbidity and mortality associated with these infections are due, in part, to the paucity of effective treatment options and attest to the need for new antibiotics targeted to overcome resistance determinants in gram-negative bacteria.
VAB is a novel boronic acid beta-lactamase inhibitor with potent in vitro activity against class A and class C beta-lactamases including KPC. 14, 33, 35 With this profile, VAB can restore the activity of MEM against many strains of CRE and has the potential to add resilience to our armamentarium of anti-CRE agents. Notably though, the structural and chemical characteristics of VAB were optimized to target the KPC enzyme specifically, and VAB does not expand the activity of MEM against Enterobacteriaceae producing class B or class D carbapenemases. 37 Initial results from phase 3 clinical trials demonstrating the efficacy and safety of MV in the treatment of cUTIs and AP are encouraging. 63, 64 However, limitations in study design and the need to achieve regulatory benchmarks 458 PHARMACOTHERAPY Volume 38, Number 4, 2018 limit generalizability to high-risk patients with MDR pathogens. In contrast to the previous standard practice of using combination therapy to treat CRE infections, 4, 6, 7 MV has been used exclusively as monotherapy, and in small retrospective series the addition of other agents to ceftazidime-avibactam has not affected outcomes. 10, 11, 13 A critically important research question is the role, if any, of combination therapy in the era of novel agents to either improve clinical outcomes or slow the emergence of resistance. Randomized studies and reports of real-world experience are urgently needed to address this knowledge gap.
To date, the MV resistant phenotype has been observed in isolates with multiple resistance determinants, 23 and it remains to be seen how frequently this multifactorial resistance emerges with more widespread use. Understanding the mechanisms and drivers of resistance will be crucial in preserving the clinical utility of MV. Although it is important not to draw conclusions from the limited data available, both MV and ceftazidime-avibactam have been associated with improved outcomes compared to regimens of older, more toxic agents in patients with CRE infections. 8, 9, [72] [73] [74] A pressing question is whether the use of one of these agents results in superior clinical outcomes compared to use of the other. The role and spectrum of activity of these co-formulated products are dependent not only on the novel inhibitor but also on the companion agent. In this respect, MV may represent the stronger antibiotic backbone. The emergence of KPC resistance to ceftazidime-avibactam has already been described. 10, 58 At centers experiencing multidrug resistance, MV or one of the novel anti-CRE agents in late-stage development (imipenem-relebactam, plazomicin, eravacycline, cefiderocol) may represent an effective alternative. On the other hand, at centers with a high prevalence of OXA-48-like carbapenemases, ceftazidime-avibactam may remain a suitable frontline option for CRE infections. 80 All beta-lactam/ beta-lactam inhibitor combinations appear to be vulnerable to porin inactivation and efflux. 23, 80 Novel anti-CRE agents from different classes are needed to address this unmet need. Moving forward, nuanced approaches to therapeutic decision-making that incorporate patient-specific factors, antimicrobial PK/PD, local epidemiology, and strain genetics will be important in optimizing patient outcomes and prolonging the life of novel agents.
